Article Text

Download PDFPDF
Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life
  1. C J Malkin1,
  2. P J Pugh1,
  3. P D Morris1,
  4. K E Kerry2,
  5. R D Jones2,
  6. T H Jones2,*,
  7. K S Channer1
  1. 1Department of Cardiology, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
  2. 2Academic Unit of Endocrinology, Hormone and Vascular Biology Group, Division of Genomic Medicine, University of Sheffield, Sheffield, UK
  1. Correspondence to:
    Dr K S Channer
    M131, Cardiology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK; email:


Background: Low serum testosterone is associated with several cardiovascular risk factors including dyslipidaemia, adverse clotting profiles, obesity, and insulin resistance. Testosterone has been reported to improve symptoms of angina and delay time to ischaemic threshold in unselected men with coronary disease.

Objective: This randomised single blind placebo controlled crossover study compared testosterone replacement therapy (Sustanon 100) with placebo in 10 men with ischaemic heart disease and hypogonadism.

Results: Baseline total testosterone and bioavailable testosterone were respectively 4.2 (0.5) nmol/l and 1.7 (0.4) nmol/l. After a month of testosterone, delta value analysis between testosterone and placebo phase showed that mean (SD) trough testosterone concentrations increased significantly by 4.8 (6.6) nmol/l (total testosterone) (p  =  0.05) and 3.8 (4.5) nmol/l (bioavailable testosterone) (p  =  0.025), time to 1 mm ST segment depression assessed by Bruce protocol exercise treadmill testing increased by 74 (54) seconds (p  =  0.002), and mood scores assessed with validated questionnaires all improved. Compared with placebo, testosterone therapy was also associated with a significant reduction of total cholesterol and serum tumour necrosis factor α with delta values of −0.41 (0.54) mmol/l (p  =  0.04) and −1.8 (2.4) pg/ml (p  =  0.05) respectively.

Conclusion: Testosterone replacement therapy in hypogonadal men delays time to ischaemia, improves mood, and is associated with potentially beneficial reductions of total cholesterol and serum tumour necrosis factor α.

  • ELISA, enzyme linked immunosorbent assay
  • HDL, high density lipoprotein
  • LDL, low density lipoprotein
  • PSA, prostate specific antigen
  • TNFα, tumour necrosis factor α

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • * Also the Centre for Diabetes & Endocrinology, Barnsley District General Hospital, Barnsley, UK

  • There is no conflict of interest